Next Article in Journal
Drug Conjugates for Targeting Eph Receptors in Glioblastoma
Previous Article in Journal
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitylation as a Novel Pharmaceutical Target for Cystic Fibrosis
Previous Article in Special Issue
(Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer
Open AccessReview

Atomic Nanogenerators in Targeted Alpha Therapies: Curie’s Legacy in Modern Cancer Management

1
German Cancer Research Center (DKFZ), Division of Radiooncology/Radiobiology, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
2
German Cancer Research Center (DKFZ), Research Group Molecular Biology of Systemic Radiotherapy, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(4), 76; https://doi.org/10.3390/ph13040076
Received: 20 March 2020 / Revised: 17 April 2020 / Accepted: 21 April 2020 / Published: 23 April 2020
Atomic in vivo nanogenerators such as actinium-225, thorium-227, and radium-223 are of increasing interest and importance in the treatment of patients with metastatic cancer diseases. This is due to their peculiar physical, chemical, and biological characteristics, leading to astonishing responses in otherwise resistant patients. Nevertheless, there are still a few obstacles and hurdles to be overcome that hamper the broader utilization in the clinical setting. Next to the limited supply and relatively high costs, the in vivo complex stability and the fate of the recoiling daughter radionuclides are substantial problems that need to be solved. In radiobiology, the mechanisms underlying treatment efficiency, possible resistance mechanisms, and late side effect occurrence are still far from being understood and need to be unraveled. In this review, the current knowledge on the scientific and clinical background of targeted alpha therapies is summarized. Furthermore, open issues and novel approaches with a focus on the future perspective are discussed. Once these are unraveled, targeted alpha therapies with atomic in vivo nanogenerators can be tailored to suit the needs of each patient when applying careful risk stratification and combination therapies. They have the potential to become one of the major treatment pillars in modern cancer management. View Full-Text
Keywords: atomic in vivo nanogenerators; α-emitters; thorium-227 (227Th); actinium-225 (225Ac); radium-223 (223Ra); coordination chemistry; nuclear recoil effect; radiopharmaceuticals; targeted alpha therapies (TAT) atomic in vivo nanogenerators; α-emitters; thorium-227 (227Th); actinium-225 (225Ac); radium-223 (223Ra); coordination chemistry; nuclear recoil effect; radiopharmaceuticals; targeted alpha therapies (TAT)
Show Figures

Graphical abstract

MDPI and ACS Style

Roscher, M.; Bakos, G.; Benešová, M. Atomic Nanogenerators in Targeted Alpha Therapies: Curie’s Legacy in Modern Cancer Management. Pharmaceuticals 2020, 13, 76.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop